Mythic Therapeutics

Mythic Therapeutics is a biotechnology company focused on developing a new generation of antibody-drug conjugates (ADCs) for treating various types of cancers. The company's proprietary FateControl technology aims to improve the delivery of cytotoxic payloads to tumor cells by enhancing the internalization and release of ADCs within cancer cells. This approach is designed to increase the therapeutic efficacy of ADCs while minimizing their impact on healthy tissues, thereby expanding the range of molecular targets and patient populations that can benefit from these targeted therapies.

Mythic's lead product candidate, MYTX-011, is a cMET-targeting ADC being developed for the treatment of non-small cell lung cancer (NSCLC). MYTX-011 comprises an engineered anti-cMET antibody conjugated to the potent cytotoxic drug monomethyl auristatin E (MMAE). preclinical studies have demonstrated that MYTX-011 exhibits higher internalization in cMET-positive tumor cells and superior efficacy compared to other cMET-targeting ADCs, including a greater than three-fold increase in efficacy in mouse models of NSCLC. MYTX-011 also demonstrated favorable pharmacokinetics and a toxicity profile consistent with other MMAE-based ADCs.

In April 2023, Mythic announced the dosing of the first patient in the Phase 1 KisMET-01 clinical trial, a multi-center, dose-escalation, and dose-expansion study evaluating MYTX-011 in patients with locally advanced, recurrent, or metastatic NSCLC. The trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of MYTX-011, including in patients with NSCLC tumors overexpressing cMET or harboring MET amplifications or exon 14 skipping mutations.

In September 2023, the US Food and Drug Administration (FDA) granted Fast Track designation to MYTX-011 for the treatment of NSCLC patients with cMET overexpression, encompassing all levels of cMET expression. This designation is intended to facilitate the development and expedite the review of drugs for serious conditions with unmet medical needs.